FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

Автор: U.S. Food and Drug Administration

Загружено: 2026-02-10

Просмотров: 264

Описание: Join FDA experts from the Office of Cosmetics and Colors for a comprehensive presentation on cosmetic product regulation in the United States. This session provides essential information about the Modernization of Cosmetics Regulation Act (MoCRA), landmark legislation passed in December 2022 that gave FDA significant new authority over cosmetics for the first time since 1938.

What You'll Learn:
• U.S. cosmetics regulatory framework and FDA's statutory authority
• Facility registration and product listing requirements under MoCRA
• Adverse event reporting procedures for industry and consumers
• Good Manufacturing Practices (GMP) regulations and safety substantiation
• New labeling requirements, including professional-use designations and contact information
• Mandatory recall authority and records inspection provisions
• Small business exemptions and compliance deadlines

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

Доступные форматы для скачивания:

Скачать видео

Информация по загрузке:

Скачать аудио

Похожие видео

Medical Device Quality Management System Regulation Risk Management

Medical Device Quality Management System Regulation Risk Management

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

Public Meeting: Reauthorization of the Biosimilar User Fee Act

Public Meeting: Reauthorization of the Biosimilar User Fee Act

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

Medical Device Quality Management System Regulation Design and Development

Medical Device Quality Management System Regulation Design and Development

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

2025 FDA Achievements

2025 FDA Achievements

FDA Celebrates 120 Years

FDA Celebrates 120 Years

FDA Direct: эти 9 препаратов получили национальные приоритетные ваучеры

FDA Direct: эти 9 препаратов получили национальные приоритетные ваучеры